About Ab Initio
Ab Initio is a Healthcare company based in San Francisco (United States) founded in 2015, and was acquired by Ligand Pharmaceuticals in July 2019. GPCR-modulating protein agents and immuno-oncology drugs are developed. Ab Initio offers products and services including OmniRat, OmniMouse, OmniChicken, and Omni dAb. Its focus areas include Life Sciences, Immunotherapy, Antibody and Disease-Targeting. Its legal entity is OmniAb, Inc. Its competitors include C4 Therapeutics, Erasca and MiRagen; 3 of its 3 listed competitors have raised funding.
Company details
Ab Initio was founded in 2015 in San Francisco, United States, within the biotechnology sector. A directed evolution display-based platform is utilized alongside protein receptor biochemistry techniques for discovering therapeutics. Focus is placed on antibodies that activate or inactivate G-protein coupled receptors, as well as multispecific agents for cancer immunotherapy engaging innate and adaptive immune responses. A collaboration with Pfizer was announced in December 2016 for GPCR antibody development.
- Headquarters San Francisco, United States
- Stage Acquired
- SectorsHealthcare
- Website aibio.com
- Social LinkedIn X
- Acquired by Ligand Pharmaceuticals (Jul 2019)
- Legal Name Omniab, Inc.
- Investors
- Acquired byLigand Pharmaceuticals
(Jul 2019)
Products & Services of Ab Initio
Ab Initio offers a comprehensive portfolio of products and services, including OmniRat, OmniMouse, OmniChicken, and Omni dAb.
Transgenic rat platform for producing human antibodies.
Transgenic mouse system for antibody discovery research.
Transgenic chicken host for diverse antibody repertoires.
Platform for single-domain antibody generation and applications.
Investors in Ab Initio
Ab Initio has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Ligand Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pharmaceutical drugs are manufactured and developed in the United States. | 1987 | ligand.com | San Diego, United States |
Investor details for Ab Initio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Ab Initio
2 dated milestones of Ab Initio across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Ab Initio is founded.
- Exit Acquired by Ligand Pharmaceuticals.
Competitors of Ab Initio
Ab Initio has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and MiRagen.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. |
Detailed competitors of Ab Initio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Ab Initio (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ab Initio
Complete news archive for Ab Initio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ab Initio
Ab Initio was founded in 2015.
Ab Initio is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Ab Initio was founded in 2015 in San Francisco, United States, within the biotechnology sector. A directed evolution display-based platform is utilized alongside protein receptor biochemistry techniques for discovering therapeutics. Focus is placed on antibodies that activate or inactivate G-protein coupled receptors, as well as multispecific agents for cancer immunotherapy engaging innate and adaptive immune responses. A collaboration with Pfizer was announced in December 2016 for GPCR antibody development.
Ab Initio's top competitors include C4 Therapeutics, Erasca and MiRagen.
Ab Initio offers OmniRat, OmniMouse, OmniChicken, and Omni dAb.
Ab Initio has 1 investor. Key investors include Ligand Pharmaceuticals.
Ab Initio operates through Omniab, Inc..
Yes. Ab Initio was acquired by Ligand Pharmaceuticals in July 2019.